Herlev, Denmark – 16 November 2026 – RetinaLyze System is now certified under the EU Medical Device Regulation as a Class IIa medical device. TÜV SÜD Product Service GmbH, Notified Body 0123, issued RetinaLyze System A/S an EU quality management system certificate under Regulation (EU) 2017/745 on 16 October 2026. The certificate covers RetinaLyze System, the clinical decision support software that optometrists, opticians, ophthalmic nurses and eye clinics use to investigate fundus images, with its modules RetinaLyze DR Screening, RetinaLyze AMD Screening, RetinaLyze Glaucoma Screening and RetinaLyze Advanced Glaucoma.
What Class IIa means
Under the MDR, RetinaLyze System is classified as Class IIa, in the software device group. For a Class IIa device, the Notified Body assesses the manufacturer’s quality management system together with the technical documentation, and continues to assess both through periodic surveillance.
The certificate, number G15 121667 0002 Rev. 00, was issued under Annex IX, Chapter I of the MDR and is valid until 15 October 2031. RetinaLyze’s quality management system is also certified to ISO 13485:2016 by TÜV SÜD Product Service, certificate Q5 121667 0003 Rev. 01, valid until 17 September 2028.
What RetinaLyze System does
RetinaLyze System is clinical decision support for eye care professionals. It investigates potential pathological changes in the retina and optic nerve head, minor black lesions, minor white lesions and colour variations in the optic nerve head, which could indicate early signs of diabetic retinopathy, age-related macular degeneration and glaucoma.
The software shows its findings as an overlay on the fundus image with a colour-coded result. It does not diagnose. Its output is not to be used as the sole basis for diagnosis, treatment, referral or ruling out disease; the original image, the overlay, the patient’s history and other clinical findings are assessed by an eye care professional.
It is used in retail and clinical settings, from optical stores and primary eye care to hospitals and specialist clinics, with patients from the general population.
Validated performance
Performance was verified against eye care specialist grading, as stated in the instructions for use.
| Module | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|
| RetinaLyze DR Screening | 90.67% | 83.37% | 8.93% | 99.80% |
| RetinaLyze AMD Screening | 84.51% | 84.68% | 51.97% | 96.44% |
| RetinaLyze Glaucoma Screening | 89.63% | 76.39% | 74.85% | 90.38% |
These figures assume the fundus image meets the input, image quality and compatibility requirements in the instructions for use. In the validation, 8.93% of positive results from RetinaLyze DR Screening matched specialist grading. This mainly reflects how uncommon diabetic retinopathy was among the people tested: when a condition is rare, even a test with high sensitivity and specificity finds more possible changes than confirmed disease.
For the same reason, a negative result was very rarely wrong (NPV 99.80%). Predictive values therefore depend on how common a condition is in the people tested, as Altman and Bland set out in the BMJ in 1994, and the values for the three modules should not be compared with each other. This is one reason every result is reviewed by an eye care professional.
What it means for customers
Nothing changes in how the software works: the features customers use today stay the same.
“Moving from Class I to Class IIa means an independent Notified Body now assesses our quality system and technical documentation, and will keep doing so for as long as the certificate is valid. For the eye care professionals who use RetinaLyze every day, it’s an outside check on the software that supports their decisions. The decisions stay theirs,” says Teddy Birch Petersen, CEO of RetinaLyze System A/S.
Markets
The certificate and the CE marking it supports apply in the European Union.
About RetinaLyze
RetinaLyze System A/S is based in Herlev, Denmark. Since 2013, more than 7 million analyses have been run on RetinaLyze, and it is available in more than 20 countries. The software helps eye care professionals investigate fundus images for potential changes that could indicate early signs of diabetic retinopathy, AMD and glaucoma.
Read more at retinalyze.com.
Press contact: RetinaLyze, support@retinalyze.com, +45 71 990 321

